CYCN (STOCKS)
Cyclerion Therapeutics, Inc. Common Stock
$3.180000
-0.070000 (-2.15%)
Prev close: $3.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Regina Graul
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $13.84M
- Employees
- 1
- P/E (TTM)
- -2.32
- P/B (TTM)
- 2.03
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.21 | $-0.39 | +0.1776 | +45.82% |
|
Sep 2025 (Q3)
|
$-0.30 | $0.00 | +0.0000 | +0.00% |
|
Jun 2025 (Q2)
|
$-0.11 | $0.00 | +0.0000 | +0.00% |
|
Sep 2023 (Q3)
|
$-0.93 | $-0.34 | -0.5934 | -176.29% |
Financial Statements
| Revenues | $1.99M |
| Nonoperating Income/Loss | $1.45M |
| Operating Expenses | $8.72M |
| Research and Development | $1.65M |
| Other Operating Expenses | $7.07M |
| Operating Income/Loss | -$6.73M |
| Income/Loss From Continuing Operations After Tax | -$5.28M |
| Income/Loss From Continuing Operations Before Tax | -$3.43M |
| Net Income/Loss | -$5.28M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$5.28M |
| Net Income/Loss Available To Common Stockholders, Basic | -$5.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.36 |
| Diluted Earnings Per Share | -$1.36 |
| Basic Average Shares | 10,711,000 |
| Diluted Average Shares | 10,711,000 |
| Assets | $8.51M |
| Current Assets | $3.09M |
| Prepaid Expenses | $255.00K |
| Other Current Assets | $2.83M |
| Noncurrent Assets | $5.42M |
| Fixed Assets | $66.00K |
| Other Non-current Assets | $5.35M |
| Liabilities | $1.71M |
| Current Liabilities | $1.71M |
| Accounts Payable | $457.00K |
| Wages | $21.00K |
| Other Current Liabilities | $1.24M |
| Noncurrent Liabilities | $0.00 |
| Commitments and Contingencies | $0.00 |
| Equity | $6.79M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.79M |
| Liabilities And Equity | $8.51M |
| Net Cash Flow From Operating Activities | -$3.52M |
| Net Cash Flow From Operating Activities, Continuing | -$3.52M |
| Net Cash Flow From Investing Activities | $333.00K |
| Net Cash Flow From Investing Activities, Continuing | $333.00K |
| Net Cash Flow From Financing Activities | $2.77M |
| Net Cash Flow From Financing Activities, Continuing | $2.77M |
| Net Cash Flow | -$417.00K |
| Net Cash Flow, Continuing | -$417.00K |
| Comprehensive Income/Loss | -$5.28M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$5.28M |
| Other Comprehensive Income/Loss | -$976.00K |